These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22068258)

  • 21. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
    Garg R; Chen W; Pendergrass M
    Diabetes Care; 2010 Nov; 33(11):2349-54. PubMed ID: 20682680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
    Gudipaty L; Rosenfeld NK; Fuller CS; Gallop R; Schutta MH; Rickels MR
    Diabetes Care; 2014 Sep; 37(9):2451-8. PubMed ID: 24969577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
    Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
    Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 28. Journal withdraws article after complaints from drug manufacturers.
    Hawkes N
    BMJ; 2011 Apr; 342():d2335. PubMed ID: 21482597
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment with new preparations against type 2 diabetes not sufficiently documented].
    Karlsson EA; Palmér M; Malmström R
    Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713
    [No Abstract]   [Full Text] [Related]  

  • 30. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exenatide-induced acute pancreatitis.
    Ayoub WA; Kumar AA; Naguib HS; Taylor HC
    Endocr Pract; 2010; 16(1):80-3. PubMed ID: 19703814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
    Lage MJ; Fabunmi R; Boye KS; Misurski DA
    Adv Ther; 2009 Feb; 26(2):217-29. PubMed ID: 19219409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
    Shetty AS; Nandith A; Snehalath C; Ramachandran A
    J Assoc Physicians India; 2013 Aug; 61(8):543-4. PubMed ID: 24818338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Incretin related agents for treatment of diabetes mellitus].
    Miyagawa J; Miuchi M; Nanba M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute necrotizing pancreatitis associated with vildagliptin.
    Kunjathaya P; Ramaswami PK; Krishnamurthy AN; Bhat N
    JOP; 2013 Jan; 14(1):81-4. PubMed ID: 23306341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
    Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 40. Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
    Prescrire Int; 2011 Nov; 20(121):267. PubMed ID: 22066314
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.